The National Law Review

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show ...
AZoNano

Precision Chemistry in Peptide and Oligonucleotide Synthesis

Advancements in peptide and oligonucleotide synthesis via precision chemistry are transforming therapeutic development by ...
Nasdaq

Biogen Announces Promising Interim Phase 1 Results for Salanersen (BIIB115/ION306) in Treatment of Spinal Muscular Atrophy

Biogen Inc. announced positive interim results from a Phase 1 study of salanersen (BIIB115/ION306), a novel antisense oligonucleotide for treating spinal muscular atrophy (SMA). The data show that ...
Seeking Alpha

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...
FierceBiotech

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...
Business Wire

Oligonucleotide Synthesis Market Research Report 2025 with Executive and Consultant Guides, & Profiles of 65+ Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market: Forecast by Oligo Length, Application, Category, Type, Product, and Region, with Executive and Consultant Guides" report has been added ...